Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

Jessica N. Hartnett; Matthew L. Boisen; Darin Oottamasathien; Abigail B. Jones; Molly M. Millett; Diana S. Nelson; Ivana J. Muncy; Augustine Goba; Mambu Momoh; Mohammed Fullah; Chad E. Mire; Joan B. Geisbert; Thomas W. Geisbert; Debra L. Holton; Julie A. Rouelle; Chandrika B. Kannadka; Ashley A. Reyna; Lina M. Moses; Sheik Humarr Khan; Sahr M. Gevao; Donald S. Grant; James E. Robinson; Christian Happi; Kelly R. Pitts; Robert F. Garry; Luis M. Branco

doi:10.2217/fvl.15.41

Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

Jessica N. Hartnett, Matthew L. Boisen, Darin Oottamasathien, Abigail B. Jones, Molly M. Millett, Diana S. Nelson, Ivana J. Muncy, Augustine Goba, Mambu Momoh, Mohammed Fullah, Chad E. Mire, Joan B. Geisbert, Thomas W. Geisbert, Debra L. Holton, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Reyna, Lina M. Moses, Sheik Humarr Khan, Sahr M. GevaoDonald S. Grant, James E. Robinson, Christian Happi, Kelly R. Pitts, Robert F. Garry, Luis M. Branco

Microbiology And Immunology

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

Original language	English (US)
Pages (from-to)	559-584
Number of pages	26
Journal	Future Virology
Volume	10
Issue number	5
DOIs	https://doi.org/10.2217/fvl.15.41
State	Published - May 1 2015

Keywords

Lassa fever
Lassa virus
arenaviruses
bioterrorism
diagnostics
epidemiology
hemorrhagic fever
public health
therapeutics
vaccines

ASJC Scopus subject areas

Virology

Access to Document

10.2217/fvl.15.41

Cite this

Hartnett, J. N., Boisen, M. L., Oottamasathien, D., Jones, A. B., Millett, M. M., Nelson, D. S., Muncy, I. J., Goba, A., Momoh, M., Fullah, M., Mire, C. E., Geisbert, J. B., Geisbert, T. W., Holton, D. L., Rouelle, J. A., Kannadka, C. B., Reyna, A. A., Moses, L. M., Khan, S. H., ... Branco, L. M. (2015). Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virology, 10(5), 559-584. https://doi.org/10.2217/fvl.15.41

Hartnett, JN, Boisen, ML, Oottamasathien, D, Jones, AB, Millett, MM, Nelson, DS, Muncy, IJ, Goba, A, Momoh, M, Fullah, M, Mire, CE, Geisbert, JB, Geisbert, TW, Holton, DL, Rouelle, JA, Kannadka, CB, Reyna, AA, Moses, LM, Khan, SH, Gevao, SM, Grant, DS, Robinson, JE, Happi, C, Pitts, KR, Garry, RF & Branco, LM 2015, 'Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever', Future Virology, vol. 10, no. 5, pp. 559-584. https://doi.org/10.2217/fvl.15.41

@article{349d7dc1532b4e08b3fbaa5c65cbfd2b,

title = "Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever",

abstract = "Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformit{\'e} Europ{\'e}enne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.",

keywords = "Lassa fever, Lassa virus, arenaviruses, bioterrorism, diagnostics, epidemiology, hemorrhagic fever, public health, therapeutics, vaccines",

author = "Hartnett, {Jessica N.} and Boisen, {Matthew L.} and Darin Oottamasathien and Jones, {Abigail B.} and Millett, {Molly M.} and Nelson, {Diana S.} and Muncy, {Ivana J.} and Augustine Goba and Mambu Momoh and Mohammed Fullah and Mire, {Chad E.} and Geisbert, {Joan B.} and Geisbert, {Thomas W.} and Holton, {Debra L.} and Rouelle, {Julie A.} and Kannadka, {Chandrika B.} and Reyna, {Ashley A.} and Moses, {Lina M.} and Khan, {Sheik Humarr} and Gevao, {Sahr M.} and Grant, {Donald S.} and Robinson, {James E.} and Christian Happi and Pitts, {Kelly R.} and Garry, {Robert F.} and Branco, {Luis M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = may,

day = "1",

doi = "10.2217/fvl.15.41",

language = "English (US)",

volume = "10",

pages = "559--584",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

AU - Hartnett, Jessica N.

AU - Boisen, Matthew L.

AU - Oottamasathien, Darin

AU - Jones, Abigail B.

AU - Millett, Molly M.

AU - Nelson, Diana S.

AU - Muncy, Ivana J.

AU - Goba, Augustine

AU - Momoh, Mambu

AU - Fullah, Mohammed

AU - Mire, Chad E.

AU - Geisbert, Joan B.

AU - Geisbert, Thomas W.

AU - Holton, Debra L.

AU - Rouelle, Julie A.

AU - Kannadka, Chandrika B.

AU - Reyna, Ashley A.

AU - Moses, Lina M.

AU - Khan, Sheik Humarr

AU - Gevao, Sahr M.

AU - Grant, Donald S.

AU - Robinson, James E.

AU - Happi, Christian

AU - Pitts, Kelly R.

AU - Garry, Robert F.

AU - Branco, Luis M.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

AB - Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

KW - Lassa fever

KW - Lassa virus

KW - arenaviruses

KW - bioterrorism

KW - diagnostics

KW - epidemiology

KW - hemorrhagic fever

KW - public health

KW - therapeutics

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84930323632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930323632&partnerID=8YFLogxK

U2 - 10.2217/fvl.15.41

DO - 10.2217/fvl.15.41

M3 - Review article

AN - SCOPUS:84930323632

SN - 1746-0794

VL - 10

SP - 559

EP - 584

JO - Future Virology

JF - Future Virology

IS - 5

ER -

Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this